How long does hydrocodone stay in the body
Similarly, in the event of any breakthroughs in the development or invention of alternative drugs for these therapeutic categories, we may be exposed to the risk of our products becoming obsolete or being substituted by these alternatives.
Some of our dossier sale agreements and supply agreements typically provide that in the event market circumstances, generic competition, product innovation or other like factors force our products or our distributors to not be competitive in the market, our distributors and customers have a right to prematurely terminate their respective agreements with us and return how long does hydrocodone stay in the body any such products which are how long does hydrocodone stay in the body so rendered uncompetitive.
Our success depends on our ability to develop and commercialize new products in a timely manner.
Our investments in research and development to build our product how long does hydrocodone stay in the body pipeline may not achieve expected profits. Our success largely depends upon our ability to commercialize new pharmaceutical products in India how long does hydrocodone stay in the body and across various markets around the world. We must successfully develop, test and manufacture generic products and all of our products must meet and continue to comply with regulatory and safety standards and receive regulatory approvals from appropriate authorities.
The process of development and commercialization of pharmaceutical formulations is time-consuming, involves significant investments and entails a high degree of business risk. Our overall profitability depends on, among other things, our ability to introduce new generic products in a timely manner, to continue to manufacture products cost-efficiently and to manage the life cycle of our global generic portfolio. We increasingly invest greater resources to develop our new products pipeline, both through our own efforts and through collaborations with third parties, which results in higher risks. The time from commencing R&D activity to a possible commercial launch of a product varies between six months to three years and involves multiple stages during which the product may be abandoned as a result of factors such as developmental problems, the inability to achieve our clinical goals, the inability to obtain necessary regulatory approvals in a timely manner or at all, and the inability to produce and market such new products successfully and profitably. Our products currently under development, if and when fully developed and tested, may not perform as we expect. Our investment in the R&D of new products may result in significant cost with no assurances of future revenues or profits. Delays in any part of the process or our inability to obtain regulatory approvals for our products could have a material adverse effect on our business, prospects, results of operations and financial condition by restricting or delaying the introduction of new products. 5.If we elect to develop or sell a generic product prior to the final resolution of outstanding patent litigation, we could be subject to liabilities for damages. At times we seek approval to market generic products before the expiration of patents for those products, based on our belief that such patents are invalid, unenforceable, or would not be infringed by our products.
Cleanse phentermine viagra xanax
Guaranteed lowest price tramadol
Farmakologija com ankete inc 49 buy generic hydrocodone online
Florida oxycontin lawyer
Description pill tramadol